12345...102030...


Bitcoin Price Forecast and Analysis – September 19, 2017

Bitcoin (BTC) is once again nearing the all-important $4,000 threshold, a significant bounce-back compared to last week’s low point of $3,200 that came as a result of China’s crackdown on initial coin offerings (ICO).

Of course, the brightest cryptocurrency future has to include the Chinese market and its loads of cash, but for now, Bitcoin should be able to pull itself up steadily back to the $5,000 mark without China’s help.

Cryptocurrencies will need to find a way to reintegrate themselves into the Chinese market in the long term. BTC prices benefit from a surge in.

The post Bitcoin Price Forecast and Analysis – September 19, 2017 appeared first on Profit Confidential.

Original post:

Bitcoin Price Forecast and Analysis – September 19, 2017

Litecoin Price Forecast and Analysis – September 19, 2017

While most of the cryptocurrency market hit the snooze button on Monday, Litecoin traders were up and about. More than $408.0 million worth of LTC coins changed hands as the Litecoin to USD exchange rate jumped roughly 4.11%.

Litecoin also gained around 2.9% against Bitcoin, possibly balancing for the different speeds in their recoveries. Nevertheless, it’ll be a long time before the two currencies are disentangled.

To this day, investors perceive Litecoin as “the silver to Bitcoin’s gold.”

There were moments when the market started to value LTC based on Litecoin news alone (which led to all-time highs), but then China rained on everyone’s parade by shutting down.

The post Litecoin Price Forecast and Analysis – September 19, 2017 appeared first on Profit Confidential.

The rest is here:

Litecoin Price Forecast and Analysis – September 19, 2017

Ripple Price Forecast and Analysis – September 19, 2017

Ripple prices took a break from the high drama of recent weeks, ending the last 24 hours a slight twitch up to around $0.185670. The stability of the Ripple to USD exchange rate is a constructive signal for investors that grew nervous after the Chinese crackdown.

After all, XRP fell by double digits only a few days ago, putting our annual Ripple price prediction in jeopardy. Cooler heads have prevailed since then, and Ripple is back above where it was a.

The post Ripple Price Forecast and Analysis – September 19, 2017 appeared first on Profit Confidential.

Read this article:

Ripple Price Forecast and Analysis – September 19, 2017

Ripple Price Forecast and Analysis – September 18, 2017

For the first time in a week, cryptocurrencies stuck their heads above water. The Ripple-to-USD exchange rate jumped 7.13% to $0.188622, while simultaneously falling 4.22% against Bitcoin.

China’s ban on cryptocurrency exchanges was once again the biggest piece of Ripple news. This time, however, prices moved to the upside, because investors realized that last week’s reaction was a little excessive (if not downright apocalyptic).

What makes it worse is that Ripple didn’t deserve the beating it took last week.

For one thing, less than five percent of its.

The post Ripple Price Forecast and Analysis – September 18, 2017 appeared first on Profit Confidential.

See the rest here:

Ripple Price Forecast and Analysis – September 18, 2017

Litecoin Price Forecast and Analysis – September 18, 2017

Despite China taking a bat to Litecoin’s knees, the Litecoin-to-USD exchange rate bounced up about 9.68% to roughly $51.89. “What explosive piece of Litecoin news caused this rally?” you ask.

Oddly, nothing in particular.

This was a see-saw moment for Litecoin prices. After tilting hard towards the bearish side last week, investors pushed off the bottom to bring LTC prices back above $50.00.

Perhaps they thought the reaction to China’s ban on cryptocurrency exchanges was a tad overblown. Or perhaps they thought LTC is a buy under $50.00.

In either case, the surge in prices is likely to continue now that the fog of uncertainty has lifted.

Last week, we knew nothing.

The post Litecoin Price Forecast and Analysis – September 18, 2017 appeared first on Profit Confidential.

See the article here:

Litecoin Price Forecast and Analysis – September 18, 2017

Ethereum Price Forecast and Analysis – September 18, 2017

Hallelujah! After a week of non-stop pain, investors finally moved past China’s ban on cryptocurrency exchanges. They bid up prices, bet on fundamentals, and were rewarded with flashing green numbers on their trading monitors.

For instance, the Ethereum-to-USD exchange rate jumped 17% to $280.69 on Sunday.

Considering that it slipped below $200.00 on Friday, the rebound was particularly steep. Who said there’s no resilience in cryptocurrencies? It took less than a week to shrug off China’s ban, which was definitely more than a flesh wound.

Ethereum gained.

The post Ethereum Price Forecast and Analysis – September 18, 2017 appeared first on Profit Confidential.

More:

Ethereum Price Forecast and Analysis – September 18, 2017

This Cryptocurrency Could Be the Next Bitcoin

Bitcoin Turned $25 into $34 Million
Bitcoin, bitcoin, bitcoin, bitcoin, bitcoin, bitcoin…bitcoin. It’s all that anyone seems to be talking about, yet the volatility of Bitcoin is terrifying. Double-digit swings are a normal occurrence. And no one can explain what it does, at least not in plain English.

But there’s no denying that Bitcoin is a gold mine.

Investors who bought BTC coins in 2013 would have gained 2,411% by now. And those who “mined” the currency made even bigger returns..

The post This Cryptocurrency Could Be the Next Bitcoin appeared first on Profit Confidential.

Read this article:

This Cryptocurrency Could Be the Next Bitcoin

Ripple Price Forecast and Analysis – September 15, 2017

As with the rest of the cryptocurrency market, China takes center stage in our Ripple news update. It’s the only thing that matters at the moment, though one could argue that XRP is unfairly caught in the crossfire.

After all, less than five percent of Ripple’s trading volume comes from within China. Add that to the fact that the ban is on trading, and not “blockchain activities,” and it seems like Ripple’s eastward expansion is still on track.

What the regulators objected to was the “disorder” of cryptocurrency exchanges. They aren’t fond of chaos. But.

The post Ripple Price Forecast and Analysis – September 15, 2017 appeared first on Profit Confidential.

View original post here:

Ripple Price Forecast and Analysis – September 15, 2017

Ethereum Price Forecast and Analysis – September 15, 2017

China is the only Ethereum news that matters today, as crypto markets continue to reel from a Chinese crackdown on local exchanges. The entire crypto market is under siege.

Ethereum to USD prices are down about 20.85% and Ethereum to Bitcoin prices dropped roughly 3.1%, suggesting that investors are coalescing around the market leader in times of uncertainty.

With ETH prices touching a two-month low at $201.62, many are wondering when the pain will stop. The truth is, there might be more pain to come.

Two of China’s largest cryptocurrency exchanges have not yet shut.

The post Ethereum Price Forecast and Analysis – September 15, 2017 appeared first on Profit Confidential.

Here is the original post:

Ethereum Price Forecast and Analysis – September 15, 2017

Ethereum Price Forecast and Analysis – September 19, 2017

As the dust settles from China’s crackdown on cryptocurrencies, Ethereum looks poised for a rally that could send it across the $300.00 level. However, the situation remains tenuous.

The Chinese ban confirmed the worst fears of some investors—that central banks and other vested interests will regulate against cryptocurrencies to keep their hold on power.

It’s not an unreasonable fear, but I should add that regulators only banned yuan to crypto exchanges, not the existence of blockchain itself. That may sound like a difference without a distinction, but it could be.

The post Ethereum Price Forecast and Analysis – September 19, 2017 appeared first on Profit Confidential.

Follow this link:

Ethereum Price Forecast and Analysis – September 19, 2017

Molecular Medicine – Graduate School of Biomedical …

The Department of Molecular Medicine in the Institute of Biotechnology (IBT) was established in 1994 to administer a program to train graduate students at the interface of basic and clinical sciences with an emphasis on biomedical research focused on discovering the molecular mechanisms underlying human disease and to serve as a platform for the development of novel treatment or prevention approaches. To date, our program has awarded over 120 doctoral degrees. Our graduates are placed in top-tier research universities and pharmaceutical companies across the United States and Europe. Our faculty have been successful in securing tens of millions of dollars from private and federal agencies including the National Institutes of Health, the National Science Foundation, and the Department of Defense.

Now also located in the South Texas Research Facility (STRF), we offer a research-oriented, interdisciplinary program of study in the areas of cancer and aging and their prevention. Specific areas of study include: cell (and hormone) signaling, gene expression, epigenetics, cell cycle and checkpoint controls, DNA damage repair and associated stress responses, and regulated protein turnover. Under new leadership, Dr. Tim Huang is expanding our research to include a Systems approach to molecular medicine that offers students an integrated training program spanning molecular and cellular biology, quantitative biology, computational biology, and genomics.

Our goal is to educate and train the next generation of graduate students who will change the face of biomedical research and invent new ways to treat and prevent human diseases.

Recent Publications with High Impact Factors

Xiaowen Zhang, Huai-Chin Chiang, Yao Wang, Chi Zhang, Sabrina Smith, Xiayan Zhao, Sreejith J. Nair, Joel Michalek, Ismail Jatoi, Meeghan Lautner, Boyce Oliver, Howard Wang, Anna Petit, Teresa Soler, Joan Brunet, Francesca Mateo, Miguel Angel Pujana, Elizabeth Poggi, Krysta Chaldekas, Claudine Isaacs, Beth N. Peshkin, Oscar Ochoa, Frederic Chedin, Constantine Theoharis, Lu-Zhe Sun, Tyler J. Curiel, Richard Elledge, Victor X. Jin, Yanfen Hu & Rong Li. (2017). Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis. Nature Communications. 8, 15908 doi:10.1038/ncomms15908.

Araki, K., Morita, M., Bederman, A. G., Konieczny, B. T., Kissick, H. T., Sonenberg, N., & Ahmed, R. (2017). Translation is actively regulated during the differentiation of CD8 effector T cells. Nature Immunology. doi:10.1038/ni.3795

Hsu Y-T, Osmulski, P.A., Wang Y., Huang Y-W, Liu L., Ruan J., Jin V.X., B. Kirma N.B., Gaczynska M. E., and Huang T. H-M (2017) EGFR-Dependent Regulated Intramembrane Proteolysis of EpCAM-Response. Cancer Res. 77 (7):1777.

Huang RL, Su PH, Liao YP, Wu TI, Hsu YT, Lin WY, Wang HC, Weng YC, Ou YC, Huang TH, Lai HC (2017) Integrated Epigenomics Analysis Reveals a DNA Methylation Panel for Endometrial Cancer Detection Using Cervical Scrapings. Clin Cancer Res 23(1):263-272.

Noonepalle SK, Gu F, Lee EJ, Choi JH, Han Q, Kim J, Ouzounova M, Shull AY, Pei P, Hsu PY, Kolhe R, Shi F, Choi J, Chiou K, Huang HM, Korkaya H, Deng L, Xin HB, Huang S, Thangaraju M, Sreekumar A, Ambs S, Tang SC, Munn DH, Shi H (2017) Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers. Cancer Immunology Research 5 (4) 330-344

Recently Awarded Grants

A Dual Function Switch in reproductive biology NIH – National Cancer Institute, 8/1/17, $228,750 Rong Li, Ph.D. and Yanfen Hu, Ph.D.

Crosstalk between BRCA1 and transcription in breast cancer NIH – National Cancer Institute, 7/10/17, $411,463 Rong Li, Ph.D.

Understanding Drug Resistance in BRCA1 Associated Cancer Therapy Army Medical Research Acquisition Activity, 9/30/17, $583,314 Yanfen Hu, Ph.D.

Understanding Drug Resistance in BRCA1 Associated Cancer Therapy Army Medical Research Acquisition Activity, 9/30/17, $331,689 Rong Li, Ph.D.

Targeting Enhancer Activation Machinery in Breast Cancer Hormone Resistance Voelcker Fund, 7/1/17, $450,000 Zhijie Liu, Ph.D.

Systems Analysis of Epigenomic Architecture in Cancer Progression NIH – National Cancer Institute, 5/15/17, $9,119,402 Tim Huang, Ph.D.& Victor Jin, Ph.D.

Precision Targeting of MED12-Mutant CLL with Notch Inhibitors William & Ella Owens Foundation of America, 3/15/17, $100,000 Thomas Boyer, Ph.D.

Regulation of ER-Beta Signaling in Carcinogenesis NIH – National Cancer Institute, 2/1/17, $2,397,840 Rong Li, Ph.D.

Read more:

Molecular Medicine – Graduate School of Biomedical …

Home – Weatherall Institute of Molecular Medicine

The mission of the MRC Weatherall Institute of Molecular Medicine (WIMM) is to undertake internationally competitive research into the processes underlying normal cell and molecular biology and to determine the mechanisms by which these processes are perturbed in inherited and acquired human diseases. It is also our mission to translate this research to improve human health. The WIMM is uniquely placed among biomedical institutes throughout the world in its pioneering vision of combining outstanding clinical research with excellent basic science. The WIMM Faculty currently includes an equal mixture of scientists and clinicians working together and in collaboration with the National Institute of Health Research, the NHS and commercial companies with the aim of improving the diagnosis and treatment of human diseases. The major topics of current research include haematology, immunology, stem cell biology, oncology and inherited human genetic diseases. The Institute benefits from strategic support from the MRC.

The Institute values communication with members of the broader scientific community and the general public and with the support of the Medical Research Council (MRC) we have commissioned three short videos to explain our mission.

Researchers from RDM kick off a week-long science extravaganza today at The Royal Society Summer Science Exhibition. The team will be exhibiting a unique blend of genetics and virtual reality on their stand, DNA Origami: How do you fold a genome? The team are one of 22 exhibits at the festival a celebration of science and innovation. They will be taking visitors through the intricate world of DNA folding, using virtual reality and …

We are delighted to announce that Prof Sir David Weatherall has been awarded a GBE, making him a Knight of the Grand Cross. This is the highest rank in the Order of the British Empire and the honour has only been bestowed 16 times since 2000. Prof Sir Weatherall was recognised for his services for medicine and it is wonderful that his pioneering work and commitment to molecular medicine have been recognised in this way. David Weatherall is a …

News Archive

Applications are invited for a highly motivated professional seeking to develop a career in Health and Safety in a medical research setting. The Deputy Safety Officer will join a small team of core staff who look after the day-to-day management of the Institute. Working closely with the Institutes Safety Officer you will have the personal drive and initiative to advise, manage and report on all aspects of health and safety for the Institute. …

Other Vacancies

Viruses are basically packets of nucleic acid, DNA or its sister molecule RNA. Our cells have therefore evolved to recognise these molecules as a sign of virus infection. A recent study from Jan Rehwinkels lab in the MRC Human Immunology Unit has revealed a new way in which cells sense and respond to invading viruses. Layal Liverpool, a DPhil student in the Rehwinkel lab, who was involved in the work, explains more.

WIMM Blog Archive

Original post:

Home – Weatherall Institute of Molecular Medicine

Molecular Medicine | University of Maryland School of Medicine

The Graduate Program in Molecular Medicine at the University of Maryland Baltimore offers research and training opportunities with internationally-renowned scientists. Our Molecular Medicine Program is an interdisciplinary program of study leading to a Ph.D. degree. There are four different research tracks: Cancer Biology, Genome Biology, Molecular and Cell Physiology, and Toxicology and Pharmacology. Each provides for a unique interdisciplinary research and graduate training experience that is ideally suited for developing scientists of the post-genomic era.

Faculty mentors in this graduate program are leaders in their respective research areas and reside in various departments and Organized Research Centers in the School of Medicine and Dental School, the Institute for Genomic Sciences (IGS), the Institute of Human Virology (IHV), the Marlene and Stewart Greenebaum Cancer Center, and the Center for Vascular and Inflammatory Diseases (CVID). The over 150 faculty in the Graduate Program in Molecular Medicine are internationally recognized for their research in biotechnology, cancer, cardiovascular and renal biology, functional genomics and genetics, membrane biology, muscle biology, neuroscience and neurotoxicology, reproduction and vascular biology.

More:

Molecular Medicine | University of Maryland School of Medicine

Master of Science (MSc) in Molecular Medicine – NTNU

International students are encouraged to attend NTNU’sOrientation Week14 – 20 August 2017.

OnMonday 21 August at 10:15there will be a welcome meeting for all new master’s students at the Faculty of Medicine and Health Sciences. This meeting takes place in auditorium KA12 in theKnowledge Centre at Campus ya.

After the welcome meeting (Monday 21 August at 12:00)there will be an orientation meeting for the MSc in Molecular Medicine. This meeting takes place in room Ls42 in the Laboratory Centre at Campus ya. It iscompulsory to attendthis meeting.

The field of molecular medicine is often referred to as “tomorrow’s medicine”. It aims to provide a molecular understanding of how normal cellular processes change, fail or are destroyed by disease. The purpose of the MSc programme is to develop knowledge and skills in cellular and molecular biology. These have applications in both research and practical clinical work, and will contribute to an increased understanding of processes, diagnostics and treatment of diseases.

The application deadline for for applicants from non-EU/non-EEA students is 1 December. The application deadline for students from EU/EEA countries is 1 March. You submit your application electronically.

The MSc in Molecular Medicine qualifies graduates for a wide range of careers, including practical clinical work and technical executive positions in hospital laboratories, and positions in pharmaceuticals and MedTech/BioTech companies.

The MSc is a two-year, full-time programme starting in the autumn semester. There are two main components: a master’s thesis worth 60 credits, and theoretical and methodological courses totalling a further 60 credits.

Contact one of our student counsellors if you have any questions about the MSc programme. Email: lbk-post@medisin.ntnu.no / Telephone: +47 72 82 07 00

Visit link:

Master of Science (MSc) in Molecular Medicine – NTNU

Donated bodies benefit UA medical students – Green Valley News

As we near the end of life, we start thinking about where wed like our treasures to go: a favorite quilt, jewelry, maybe some art work. Some people take it a step further: Last year, 400 people left their bodies to the University of Arizona.

The UA’s College of Medicine, Department of Cellular & Molecular Medicine created the Willed Body Program 50 years ago so future doctors could learn anatomy from someplace other than textbooks.

Every year, more than 120 first-year medical students from the UA visit the anatomy lab to learn lessons about the thorax, digestive system, neuroscience or the reproductive or life cycle system, said Dr. Jean Wilson, professor of Cellular and Molecular Medicine and director of the Willed Body Program. Residents and fourth-year medical students also have access to the lab so they can focus on their specialized fields.

The students also learn about biochemistry and the impact pharmacology can have on the body, Wilson said.

For students to be able to do a dissection on a whole body is unparalleled for two reasons, she said. First, it allows them to understand the common themes of the human body, but more importantly, it allows them to see all of the variations, and there are many, many variables in the human body. Being able to see the variations allows them to become better doctors.

For example, Wilson said blood vessels can split many different ways besides the textbook way, even within the same body. Theres a particular back muscle that is only present in 25 percent of people and the duct system of peoples gall bladders vary widely, too.

Typically, four to six students will work at one table, but they are encouraged to look at what the other students in their class are doing as well, Wilson said.

On Friday, medical students from the Class of 2020 held a Memorial Service to honor those who donated their bodies through the Willed Body Program. Students and staff spoke about the anonymous donors and how they wonder what they were like in life, especially as they notice their ailments or touch their hearts and hold their hands. They marveled at their willingness to provide such an invaluable gift, describing them as selfless.

They also talked about how the lessons they learned from their donors will be applied in the future and how theyll never forget them.

Medical school is much different than it used to be, Wilson said.

It used to be 30, 40, 50 years ago, med students came in, did their gross-anatomy class and, unless they were going to become a surgeon, it would be the last time theyd see inside a body, Wilson said.

Nowadays, thanks to the various imaging systems, all doctors can see whats going on in the human body and so their gross anatomy lessons are more relevant than ever, Wilson said.

Wilson stressed the program is more than anatomy. It provides life lessons.

It also helps the students confront death, sometimes for the first time, Wilson said.

There are a few restrictions to participating in the program, but for the most part, donors must be 18 or older, live in Arizona at least part-time and be enrolled in the program. The program only accepts donors if they die in-state and transportation costs are covered by the Willed Body Program. If a funeral home must be used, all costs associated with services, storage and transportation by the funeral home are the responsibility of the family.

The UA also shares donations with Arizona State University and Northern Arizona University, Wilson said.

The success of our program depends on people who are willing to donate, Wilson said. Weve been really lucky with the number of donors, but we can never predict the future, so we never discourage anyone from donating.

Original post:

Donated bodies benefit UA medical students – Green Valley News

New research program receives DKK 100 million in funding from Novo Nordisk Foundation – News-Medical.net

August 24, 2017

The newly established research program, ‘Program for Translational Hematology’, has just received DKK 100 million in funding from the Novo Nordisk Foundation. The aim is to strengthen the cooperation between basic research and clinical practice, to gain new knowledge on leukemia and to make a concentrated effort to develop and test new forms of treatment. Professor Kristian Helin at DanStem and Biotech Research & Innovation Center (BRIC) is at the head of the new program, which focuses in particular on identifying new forms of treatment of the leukemia forms AML (Acute Myeloid Leukemia) and MDS (Myelodysplastic Syndrome).

‘I look forward to getting started, and I will be really busy. The great support of the program from all sides, from the university environment to the clinical research done at Rigshospitalet and the Novo Nordisk Foundation, is amazing. The program is first and foremost a main step in bridging the divide between basic research and clinical research, and we will draw on the best professional expertise from both environments. Hopefully this will enable us to meet our main objective, which is to help patients suffering from leukemia’, says Professor Kristian Helin, who stresses that Professor Kirsten Grnbk from the Department of Hematology and Professor Bo Porse from the Finsen Laboratory, both at Rigshospitalet, are main cooperation partners.

From DNA Sequencing to Phase 1 Trials and Recruitment of International Research Capacities

Kristian Helin explains that the research program will take as its starting point the characterization and use of leukemia cells, which will be collected from patients over the next few years, and the first stage of the program will consist in using this material to screen for the best possible forms of treatment. The goal is to become able to use the information about the mutations in patients’ DNA that have prompted the development of leukemia. It will be used to predict patients’ need for treatment and medicine response time, making it easier for doctors to customize the treatment of individual patients. Another ambition is to produce pre-clinical models of the leukemia by transplanting primary cells into mice.

‘The pre-clinical trials and basic research are main parts of our overall goal of finding new targets for the development of new medicine. At the same time, we want to look ahead and identify new methods when we know how the various forms of leukemia develop. We want to take our research all the way from basic research to clinical trials on human subjects’, Kristian Helin says and stresses that the research program also contains several educational perspectives. It will support the recruitment of young doctors and researchers, and strong international capacities have already been recruited for the program in the form of Professor Krister Wennerberg from the Institute for Molecular Medicine in Finland.

Focus on Diabetes and a New Name for DanStem

The research program falls under DanStem, which since its formation in 2010 has focused on basic research primarily. The researchers have determined how stem cells in the laboratory can be forced to develop in a particular direction and identified the role played by cancer stem cells in the development of various forms of cancer. Now the center is ready to take the next step and translate the research results into new, more targeted and efficient forms of treatment.

To further strengthen its translational research, the center will allocate DKK 32 million from its previous budget to the development of diabetes treatment. Professor and Director of DanStem Henrik Semb looks forward to the strengthened effort to create new results.

‘This shows that our basic research can be translated into clinical application within cancer and diabetes. The new grant and the redistribution of resources to translational research will strengthen our effort, through pre-clinical and future clinical trials, to develop new forms of treatment and cures for hematological forms of cancer and type 1 diabetes’, says Professor Henrik Semb.

DanStem has previously consisted of two sections: the Novo Nordisk Foundation Section for Basic Stem Cell Biology funded by the Novo Nordisk Foundation and the Section for Translational Stem Cell Research and Therapy funded by Innovation Fund Denmark. In connection with the new grant the two sections will be merged into one center called the Novo Nordisk Foundation Center for Stem Cell Biology, Danstem.

Original post:

New research program receives DKK 100 million in funding from Novo Nordisk Foundation – News-Medical.net

‘Shapeshifter’ that regulates blood clotting is visually captured for the first time – Bioscience Technology

We are normally born with a highly sophisticated array of molecules that act as “sentries,” constantly scanning our bodies for injuries such as cuts and bruises. One such molecular sentry, known as von Willebrand factor (VWF), plays a critical role in our body’s ability to stop bleeding.

To prevent hemorrhage or life-threatening blood clots, VWF must strike a delicate balance between clotting too little or too much. Researchers have long suspected that the mechanical forces and shear stress of blood flow could be closely-related to VWF’s function.

“In some ways, like in the movie Star Wars, VWF may be considered a Jedi knight in our body that can use ‘the force’ to guard the bloodstream,” says Timothy Springer, PhD, of Boston Children’s Hospital and Harvard Medical School (HMS).

It has not been possible to witness exactly how VWF senses and harnesses these mechanical forcesuntil now.

A team in the Boston Children’s Program in Cellular and Molecular Medicine and the HMS Department of Biological Chemistry and Molecular Pharmacology, co-led by Springer and Wesley P. Wong, PhD, has revealed exactly how VWF does its job.

Cutting-edge fluorescence imaging and microfluidic tools, developed by the team, allowed them to capture images of individual VWF molecules on camera while manipulating the molecules with life-like mechanical forces emulating natural blood flow.

The team’s findings, published in Nature Communications, reveal that VWF undergoes a two-step, shapeshifting transformation to activate blood clotting. This transformation is triggered when VWF senses certain changes in blood flow that are indicative of injury.

The closest-ever look at blood clotting

“Under normal circumstances, VWF molecules are compact and globular in shape,” says Hongxia Fu, PhD, a researcher in Springer’s lab and co-first author on the paper. “But we found that whenblood flowrate increases, VWF rapidly elongates, stretching out more and more in response to higher shear stress.”

However, elongating is not sufficient on its own to activateblood clotting. To safeguard against unnecessaryand potentially life threateningblood clots, it’s only when the tensile forces generated in the elongated VWF hit critical levels that the shapeshifter’s transformation becomes complete.

The tensile forces activate”sticky” sites along VWF, allowing it to adhere to circulating platelets, the cells that work in conjunction with VWF to clump up and stop blood loss.

Normally, the rush of blood needed to reach these critically-high tensile forces can only occur at sites of injury inside blood vessels. This specificity enables VWF to sense blood loss and activate rapidly and locally, without activating elsewhere in the body.

“If you can imagine stretching out your arms, and then opening your hands to capture platelets, that’s basically what we are seeing VWF do in response to bleeding,” says Wong. “It’s so important that this process occurs only when and where it is needed – this two-step activation process makes that possible.”

A new view on blood disease diagnostics and drugs

Yan Jiang, PhD, a postdoctoral fellow in Wong’s lab, also a co-first author on the paper, says the new findings could inspire smart drugs that are designed to treat the obstructive clotting, like deep vein thrombosis, at only diseased areas of the body.

“When you’re putting a generic drug into the circulatory system, it’s taking effect everywhere, even in places that can cause detriment,” says Jiang. “For example, anticoagulants are medically necessary in many cases to prevent blood clots from forming, but they also carry the risk of excessive bleeding. But, what if we could design a smart drug that can mimic the two-step shapeshifting of VWF and only takes effect in areas where clotting is likely to occur?”

Revealing how VWF responds to changes in flow in the highly dynamic bloodstream is a critical step to understanding the interplay between mechanical force and biology in clotting-related diseases and developing novel therapeutics.

“This experiment really represents a new platform for seeing and measuring what’s happening in thebloodon a molecular level,” says Wong. “Through the use of novel microfluidic technologies that allow us to mimic the body’s vasculature in combination with single-molecule imaging techniques, we are finally able to capture striking images that uncover the mystery of nature’s forces at work in our bodies.”

Read more from the original source:

‘Shapeshifter’ that regulates blood clotting is visually captured for the first time – Bioscience Technology

Molecular Medicine SpA (MLM) Plunges -0.73% on Aug 24 – Key Gazette

August 24, 2017 – By Henry Gaston

Shares of Molecular Medicine SpA (BIT:MLM) last traded at 0.41, representing a move of -0.73%, or -0.003 per share, on volume of 1.19M shares. After opening the trading day at 0.42, shares of Molecular Medicine SpA traded in a close range. Molecular Medicine SpA currently has a total float of 431.45 million shares and on average sees 1.28M shares exchange hands each day. The stock now has a 52-week low of 0.31 and high of 0.64.

Italy is known worldwide not just for being a country with a rich culture and heritage but most importantly, for being a nation with a competent trade and commerce conduct. It lures Molecular Medicine SpA to its market. That being said, it is surely one of the biggest assets of the European economy.

Having been tested through the toughest of times, there is so much to learn from the economy of Italy. Through the years, Italy and its equity market in particular, has helped shape Europe as a successfully thriving region.

The Italian equity market dates back as early as the 1800s. The Borsa Italiana or Piazza Affari, the main Italian stock exchange, had been founded as one of the earliest European stock exchanges in February 1808 by Viceroy of the Napoleonic Kingdom of Italy Eugne de Beauharnais.

The Borsa Italiana boasts as one of the few stock exchanges with the longest trading hours. The pre-market session begins at 8:00 a.m. and ends at 9:00 a.m. The regular session immediately follows at 9:00 a.m. and ends at 5:30 p.m. There is also a post market session that begins at 6:00 p.m. and ends at 8:30 p.m. These long trading hours provide flexible opportunities for international investors to buy and sell stocks on and from the Borsa Italiana. This is one of the reasons that Italy has one of the most successful trade and commerce environments in the world. Many investors are looking for reliable companies like Molecular Medicine SpA there.

The FTSE Milano Italia Borsa (MIB) is the free-float market-capitalization-weighted index that monitors the 40 most actively traded stocks on the Borsa Italiana. Until June 2009 when the FTSE had started operating the FTSE MIB, the S&P had operated it as the S&P/MIB.

Roughly 80% of the overall market valuation on the Borsa Italiana is included in the FTSE MIB, making it a significant economic indicator not just in Italy but in the entire European region. The FTSE MIB is rebalanced four times a year in order to maintain clear representation of the national economy. Molecular Medicine SpA stocks are carefully checked by professionals.

The Borsa Italiana had always been operated as a public entity until it was privatized in 1998. The London Stock Exchange Group had then bought it in an all-stock transaction in 2007, consolidating the Borsa Italiana and the London Stock Exchange.

Hundreds of years after its foundation, the Borsa Italiana now has an overall market valuation of about $650 billion with over 340 stocks listed on it.

Meanwhile, the FTSE MIB had posted its all-time high of 50,108.56 points in March 2000; and its all-time low of 12,362.50 points in July 2012. The meltdown in 2012 is widely attributed to the financial crisis in Spain, which had affected other European nations; and to the heightened borrowing costs in Europe.

Investing on Borsa Italiana stocks is ideal today not just for domestic investors but also for international investors. Evidently, many investors are flocking the Italian equity market to take advantage of a compelling borrowing environment.

More notable recent Molecular Medicine SpA (BIT:MLM) news were published by: Bloomberg.com which released: Berlusconi Campaigns for No as His Top Managers Back Renzi on November 23, 2016, also Prnewswire.com with their article: DiaSorin SpA Completes Acquisition of the Focus Diagnostics Molecular and published on May 13, 2016, Sacbee.com published: Discoveries: In western Sonoma County, ferment in the finest cedar chips on February 13, 2016. More interesting news about Molecular Medicine SpA (BIT:MLM) were released by: Globenewswire.com and their article: Progenics Pharmaceuticals Announces Positive Topline Results from published on March 30, 2017 as well as Indystar.coms news article titled: The man behind the Guyer Institute with publication date: December 29, 2015.

Molecular Medicine SpA is an Italy firm engaged in the medical biotechnology sector. The company has market cap of 176.89 million EUR. The Firm is active in the research, development and clinical validation of therapies for the treatment of cancer. It currently has negative earnings. The Companys activities include identification and development of bio-pharmaceuticals reducing the tumor mass and slowing down its growth, as well as the development of selective therapies to eliminate residual tumor tissue.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our daily email newsletter.

View post:

Molecular Medicine SpA (MLM) Plunges -0.73% on Aug 24 – Key Gazette

Jupiter-based Scripps researchers awarded grant to study, treat genetic disease – South Florida Business Journal


South Florida Business Journal
Jupiter-based Scripps researchers awarded grant to study, treat genetic disease
South Florida Business Journal
A division of the National Institutes of Health has awarded almost $1 million to South Florida-based researchers to develop a drug aimed at treating a genetic condition that causes tumors, severe hearing loss and impaired balance. The Scripps Research …

View original post here:

Jupiter-based Scripps researchers awarded grant to study, treat genetic disease – South Florida Business Journal

Molecular Medicine | USF Health

Our Mission

To Discover, apply and disseminate knowledge of the molecular basis of health and disease.

To Translate, this knowledge into innovative tools for the diagnosis, treatment and prevention of disease.

To Train, and mentor future scientists and health care professionals.

To Provide, a collegial and scholarly environment where students, faculty and staff thrive.

Continue reading here:

Molecular Medicine | USF Health


12345...102030...